This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Arizona State University. Active years: 2016-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2017
Title: Melissa Herbst-Kralovetz: Innovator in Mucosal Immunization
Introduction
Melissa Herbst-Kralovetz is a prominent inventor based in Phoenix, AZ (US). She has made significant contributions to the field of immunology, particularly in mucosal immunization. With a total of 2 patents, her work focuses on innovative methods to elicit immune responses.
Latest Patents
Her latest patents include groundbreaking methods for mucosal immunization. The first patent describes a method for eliciting an immune response by contacting a mucosal surface with a composition that includes an antigen, a NOD agonist, and a mucoadhesive. The NOD agonist used in this method is N-Acetyl-muramyl-L-Alanyl-D-Glutamin-n-butyl-ester, commonly known as 'Murabutide'. The second patent involves the production of a dry powder vaccine composition containing a subunit antigen with virus-like particles. This method ensures that mucosal vaccination results in an immune response that is not further enhanced by the co-inclusion of adjuvants.
Career Highlights
Melissa Herbst-Kralovetz is affiliated with Arizona State University, where she continues her research and development in immunology. Her innovative approaches have positioned her as a leader in her field, contributing to advancements in vaccine technology.
Collaborations
Throughout her career, she has collaborated with notable colleagues, including Charles Joel Arntzen and Daniel Tusé. These partnerships have further enriched her research and expanded the impact of her work.
Conclusion
Melissa Herbst-Kralovetz is a trailblazer in the field of mucosal immunization, with her patents paving the way for future advancements in vaccine development. Her contributions are vital to enhancing immune responses and improving public health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
